Monocyte Chemoattractant Protein-1 2518A/G Polymorphism

Diabetic Retinopathy Clinical Trial

— MCP-1  

Official title:

Association of Monocyte Chemoattractant Protein-1 (MCP-1)2518A/G Polymorphism With Proliferative Diabetic Retinopathy in Northern Chinese Type 2 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02077127
• Other study ID #: dongli
• Status: Completed
• Phase: N/A
• First received: June 10, 2013
• Last updated: March 3, 2014
• Start date: September 2011
• Est. completion date: April 2013

Study information

• Verified date: March 2014
• Source: Harbin Medical University
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Observational

Clinical Trial Summary

The pathogenesis of proliferative diabetic retinopathy (PDR) remains poorly understood. Recent studies have implicated that monocyte chemoattractant protein-1 (MCP-1) is associated with diabetic microvascular or macrovascular complications. However, the relationship between SNP polymorphism c.2518A/G in the MCP-1 gene with diabetic retinopathy remains controversial. In the present study, we evaluated the association of a single nucleotide polymorphism (SNP) in the MCP-1 gene with diabetic retinopathy (DR) and diabetic macular edema (DME) in Chinese population from Southern China with type 2 diabetes.

Description:

The association between polymorphism of MCP-1 c.2518A/G and DR had been reported in Japan and Korea, but their opinion were inconsistent. However there is no report in China so far. This study was designed to clarify the relationship of polymorphism of MCP-1 c.2518A/G with type 2 diabetes with or without DR. The relationship between MCP-1 c.2518A/G and different stage of DR has also been studied.This article proved that the MCP-1 c.2518G/G genotype is a susceptibility gene for DR in Chinese type 2 diabetic patients, especially the High-risk PDR. There is no association with DME and c.2518G/G.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1043
• Est. completion date: April 2013
• Est. primary completion date: February 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 41 Years to 68 Years

Eligibility

Inclusion Criteria:

• Type 2 diabetic retinopathy

• age at diagnosis =30 years and a known duration of diabetes of =5 years.

Exclusion Criteria:

• eyeball atrophy

• epimacular membrane

• age-related macular degeneration (ARMD)

• intravitreal injection medicine

• vitreous hemorrhage

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Diabetic Retinopathy
• Retinal Diseases

Locations

Country	Name	City	State
China	Harbin Medical University	Harbin	Heilongjiang

Sponsors (1)

Lead Sponsor	Collaborator
Harbin Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Genetic association	age at diagnosis of diabetes =30 years and a known duration of diabetes of =5 years.	1 year	Yes